NCT01696955 2018-12-19Cetuximab With or Without Tivantinib in Treating Patients With Head and Neck Cancer That Is Recurrent, Metastatic, or Cannot Be Removed by SurgeryNational Cancer Institute (NCI)Phase 2 Completed81 enrolled 14 charts